The goal of this study is to compare the immunogenicity and safety of sIPV administered via subcutaneous and intramuscular injection routes
Infants of 2 months old (aged 56-84 days).
Have a parent/legal guardian who has provided written informed consent after being fully informed about the study.
Be able to provide the vaccination records since birth.
The infant's mother is tested negative for HIV, syphilis, hepatitis B, and hepatitis C during or before the infant's enrollment to this study (test results obtained during pregnancy are acceptable, if provided).
History of any polio vaccination.
History of severe allergic reaction to previous vaccinations or hypersensitivity to any vaccine component.
Premature infants (born before week 37 of gestation).
History of asphyxia rescue or nervous system injury.
Sinovac Biotech Co., Ltd
Lead sponsor
Aga Khan University
Collaborator